EBITDA for Henry Schein (HSIC)
According to Henry Schein's latest reported financial statements, the company's current EBITDA (TTM) is $999.00M USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
HSIC
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$999.00M
YoY change
+6.9%
5Y CAGR
+6.7%
Peak year (2017)
$1.07B
Cumulative EBITDA
$17.83B
EBITDA history chart for Henry Schein (HSIC) from 1994 to 2025
EBITDA history table for Henry Schein (HSIC) from 1994 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $1.01B | +6.9% | ||
| 2024 | $941.00M | +7.3% | ||
| 2023 | $877.00M | -10.2% | ||
| 2022 | $977.00M | -8.5% | ||
| 2021 | $1.07B | +46.9% | ||
| 2020 | $726.81M | -20.7% | ||
| 2019 | $916.04M | +21.1% | ||
| 2018 | $756.48M | -29.3% | ||
| 2017 | $1.07B | +11.7% | ||
| 2016 | $957.51M | +5.7% | ||
| 2015 | $905.89M | +2.3% | ||
| 2014 | $885.61M | +8.0% | ||
| 2013 | $820.27M | +7.9% | ||
| 2012 | $760.41M | +6.3% | ||
| 2011 | $715.58M | +12.3% | ||
| 2010 | $637.21M | +14.2% | ||
| 2009 | $557.78M | +9.8% | ||
| 2008 | $508.18M | +5.6% | ||
| 2007 | $481.36M | +24.2% | ||
| 2006 | $387.49M | +16.6% | ||
| 2005 | $332.46M | +24.3% | ||
| 2004 | $267.55M | -0.6% | ||
| 2003 | $269.14M | +19.5% | ||
| 2002 | $225.28M | +22.8% | ||
| 2001 | $183.39M | +13.6% | ||
| 2000 | $161.38M | +9.4% | ||
| 1999 | $147.46M | +26.9% | ||
| 1998 | $116.18M | +48.4% | ||
| 1997 | $78.30M | +40.6% | ||
| 1996 | $55.70M | +28.6% | ||
| 1995 | $43.30M | -859.6% | ||
| 1994 | -$5.70M | — |
EBITDA values are taken from Henry Schein's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Henry Schein (HSIC) reported EBITDA of $1.01B – grew 6.9% year-over-year.
Over 2020–2025 (5 years), Henry Schein EBITDA expanded at a +6.7% compound annual rate, sustaining 2 straight years of year-over-year growth.
Henry Schein EBITDA declined from $1.07B in 2017 to $1.01B in 2025, a 5.9% drawdown.
The dataset's maximum EBITDA sits at $1.07B (2017); the minimum reading of -$5.70M dates to 1994.
Among 8 Healthcare peers, Henry Schein (HSIC) ranks 9th; the peer median for EBITDA is $24.21B.
Henry Schein EBITDA by Year
Henry Schein EBITDA 2025: $1.01B
Henry Schein EBITDA in 2025 was $1.01B, grew 6.9% from 2024.
Henry Schein EBITDA 2024: $941.00M
Henry Schein EBITDA in 2024 was $941.00M, grew 7.3% from 2023.
Henry Schein EBITDA 2023: $877.00M
Henry Schein EBITDA in 2023 was $877.00M, declined 10.2% below 2022.
Henry Schein EBITDA 2022: $977.00M
Henry Schein EBITDA in 2022 was $977.00M, declined 8.5% below 2021.
Henry Schein EBITDA 2021: $1.07B
Henry Schein EBITDA in 2021 was $1.07B.
See more financial history for Henry Schein (HSIC).
Sector peers — EBITDA
Companies in the same sector as Henry Schein, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Henry Schein's EBITDA?
- Latest reported EBITDA for Henry Schein (HSIC) is $999.00M (period ending December 27, 2025).
How has Henry Schein EBITDA changed year-over-year?
- Henry Schein (HSIC) EBITDA changed +6.9% year-over-year on the latest annual filing.
What is the long-term growth rate of Henry Schein EBITDA?
- Henry Schein (HSIC) EBITDA compound annual growth rate is +6.7% over the most recent 5 years available.
When did Henry Schein EBITDA hit its highest annual value?
- Henry Schein EBITDA reached its highest annual value of $1.07B in 2017.
What was Henry Schein EBITDA in 2024?
- Henry Schein (HSIC) EBITDA in 2024 was $941.00M.
What was Henry Schein EBITDA in 2025?
- Henry Schein (HSIC) EBITDA in 2025 was $1.01B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
HSIC Overview
Company profile, financial tools, and key metrics
HSIC Revenue Counter
Earns $418.06 every second. See per minute, hour, and day.
HSIC Earnings Counter
Earns $12.62 per second net profit. See per minute, hour, and day.
HSIC Economic Scale
Exceeds Equatorial Guinea's GDP. Compare with world economies.
HSIC What If Invested
What if you had invested $1,000? See historical returns from any date.
HSIC How It Makes Money
Discover visual breakdown of $13.18B in revenue — where it comes from and where it goes.
HSIC Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
HSIC Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
HSIC Daily Price Character
Balanced · 50.2% historical win rate (green days). Streaks & record days.
HSIC Buybacks
9.51% TTM buyback yield. Shareholder yield & SBC comparison.
HSIC Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.